



(86) Date de dépôt PCT/PCT Filing Date: 1998/04/30
(87) Date publication PCT/PCT Publication Date: 1998/11/12
(45) Date de délivrance/Issue Date: 2006/08/15
(85) Entrée phase nationale/National Entry: 1999/09/23
(86) N° demande PCT/PCT Application No.: JP 1998/001986
(87) N° publication PCT/PCT Publication No.: 1998/050368
(30) Priorités/Priorities: 1997/05/01 (JP9/113723);
1998/03/06 (JP10/55303)

(51) Cl.Int./Int.Cl. *C07D 235/30* (2006.01),
C07D 235/14 (2006.01), *A61K 31/4184* (2006.01)


(72) Inventeurs/Inventors:
TANIKAWA, KEIZO, JP;
KAMIKAWAJI, YOSHIMASA, JP;
HIROTSUKA, MITSUAKI, JP;
IWAMA, TAKEHISA, JP;
YAMAMOTO, AKIKO, JP;
FUJITA, YOICHIRO, JP

(73) Propriétaire/Owner:
NISSAN CHEMICAL INDUSTRIES, LTD., JP

(74) Agent: SMART & BIGGAR

(54) Titre : DERIVE DE BENZIMIDAZOLE

(54) Title: BENZIMIDAZOLE DERIVATIVE FOR TREATING ALLERGY-RELATED DISEASE



(57) Abrégé/Abstract:

A benzimidazole derivative of formula (I) or its salt wherein A is a single bond or a C₁₋₂ alkylene group (this alkylene group may optionally be substituted by a C₁₋₄ alkyl group), R⁶ is a C₁₋₄ alkyl group (this alkyl group may optionally be substituted by a phenyl group), B is a C₂₋₃ alkylene group (this alkylene group may optionally be substituted by a C₁₋₄ alkyl group), X is an oxygen atom, a sulfur atom or NR⁷ (wherein R⁷ is a nitro group, a cyano group or a C₁₋₄ alkoxy group), each of R¹ and R² which are independent of each other, is a hydrogen atom, a halogen atom, a C₁₋₄ alkyl group or a C₁₋₄ alkoxy group, E is a C₁₋₂ alkylene group (this alkylene group may optionally be substituted by a C₁₋₄ alkyl group), R³ is a phenyl group (this phenyl group may optionally be substituted by a halogen atom, a C₁₋₄ alkyl group or a C₁₋₄ alkoxy group), a C₁₋₄ alkoxy group or a benzyloxy group, each of R⁴ and R⁵ which are independent of each other, is a C₁₋₄ alkyl group (this alkyl group may optionally be substituted by a phenyl group), D is a C₁₋₂ alkylene group (this alkylene group may optionally be substituted by a C₁₋₄ alkyl group), and Ar is a phenyl group (this phenyl group may optionally be substituted by a halogen atom, a C₁₋₄ alkyl group, a C₁₋₄ alkoxy group or a trifluoromethyl group).

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 235/30, 235/14, A61K 31/415	A1	(11) International Publication Number: WO 98/50368 (43) International Publication Date: 12 November 1998 (12.11.98)		
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; vertical-align: top; padding: 5px;"> (21) International Application Number: PCT/JP98/01986 (22) International Filing Date: 30 April 1998 (30.04.98) (30) Priority Data: 9/113723 10/55303 1 May 1997 (01.05.97) 6 March 1998 (06.03.98) JP JP (71) Applicant (for all designated States except US): NISSAN CHEMICAL INDUSTRIES, LTD. [JP/JP]; 7-1, Kanda-Nishiki-cho 3-chome, Chiyoda-ku, Tokyo 101-0054 (JP). (72) Inventors; and (75) Inventors/Applicants (for US only): TANIKAWA, Keizo [JP/JP]; Nissan Chemical Industries, Ltd., Central Research Institute, 722-1, Tsuboi-cho, Funabashi-shi, Chiba 274-0062 (JP). KAMIKAWAJI, Yoshimasa [JP/JP]; Nissan Chemical Industries, Ltd., Central Research Institute, 722-1, Tsuboi-cho, Funabashi-shi, Chiba 274-0062 (JP). HIROTSUKA, Mitsuaki [JP/JP]; Nissan Chemical Industries, Ltd., Central Research Institute, 722-1, Tsuboi-cho, Funabashi-shi, Chiba 274-0062 (JP). IWAMA, Takehisa [JP/JP]; Nissan Chemical Industries, Ltd., Seibutsukagaku Kenkyusho, No. 1470, Oaza-shiraoka, Shiraoka-machi, Minamisaitama-gun, Saitama 349-0218 (JP). YAMAMOTO, </td> <td style="width: 50%; vertical-align: top; padding: 5px;"> Akiko [JP/JP]; Nissan Chemical Industries, Ltd., Seibutsukagaku Kenkyusho, No. 1470, Oaza-shiraoka, Shiraoka-machi, Minamisaitama-gun, Saitama 349-0218 (JP). FUJITA, Yoichiro [JP/JP]; Nissan Chemical Industries, Ltd., Seibutsukagaku Kenkyusho, No. 1470, Oaza-shiraoka, Shiraoka-machi, Minamisaitama-gun, Saitama 349-0218 (JP). (74) Agents: OGAWA, Toshiharu et al.; Torimoto Kogyo Building, 38, Kanda-Higashimatsushitacho, Chiyoda-ku, Tokyo 101-0042 (JP). (81) Designated States: AL, AU, CA, CN, CZ, HU, IL, KR, LT, LV, MK, MX, NO, NZ, RO, RU, SI, SK, UA, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> </td> </tr> </table>			(21) International Application Number: PCT/JP98/01986 (22) International Filing Date: 30 April 1998 (30.04.98) (30) Priority Data: 9/113723 10/55303 1 May 1997 (01.05.97) 6 March 1998 (06.03.98) JP JP (71) Applicant (for all designated States except US): NISSAN CHEMICAL INDUSTRIES, LTD. [JP/JP]; 7-1, Kanda-Nishiki-cho 3-chome, Chiyoda-ku, Tokyo 101-0054 (JP). (72) Inventors; and (75) Inventors/Applicants (for US only): TANIKAWA, Keizo [JP/JP]; Nissan Chemical Industries, Ltd., Central Research Institute, 722-1, Tsuboi-cho, Funabashi-shi, Chiba 274-0062 (JP). KAMIKAWAJI, Yoshimasa [JP/JP]; Nissan Chemical Industries, Ltd., Central Research Institute, 722-1, Tsuboi-cho, Funabashi-shi, Chiba 274-0062 (JP). HIROTSUKA, Mitsuaki [JP/JP]; Nissan Chemical Industries, Ltd., Central Research Institute, 722-1, Tsuboi-cho, Funabashi-shi, Chiba 274-0062 (JP). IWAMA, Takehisa [JP/JP]; Nissan Chemical Industries, Ltd., Seibutsukagaku Kenkyusho, No. 1470, Oaza-shiraoka, Shiraoka-machi, Minamisaitama-gun, Saitama 349-0218 (JP). YAMAMOTO,	Akiko [JP/JP]; Nissan Chemical Industries, Ltd., Seibutsukagaku Kenkyusho, No. 1470, Oaza-shiraoka, Shiraoka-machi, Minamisaitama-gun, Saitama 349-0218 (JP). FUJITA, Yoichiro [JP/JP]; Nissan Chemical Industries, Ltd., Seibutsukagaku Kenkyusho, No. 1470, Oaza-shiraoka, Shiraoka-machi, Minamisaitama-gun, Saitama 349-0218 (JP). (74) Agents: OGAWA, Toshiharu et al.; Torimoto Kogyo Building, 38, Kanda-Higashimatsushitacho, Chiyoda-ku, Tokyo 101-0042 (JP). (81) Designated States: AL, AU, CA, CN, CZ, HU, IL, KR, LT, LV, MK, MX, NO, NZ, RO, RU, SI, SK, UA, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(21) International Application Number: PCT/JP98/01986 (22) International Filing Date: 30 April 1998 (30.04.98) (30) Priority Data: 9/113723 10/55303 1 May 1997 (01.05.97) 6 March 1998 (06.03.98) JP JP (71) Applicant (for all designated States except US): NISSAN CHEMICAL INDUSTRIES, LTD. [JP/JP]; 7-1, Kanda-Nishiki-cho 3-chome, Chiyoda-ku, Tokyo 101-0054 (JP). (72) Inventors; and (75) Inventors/Applicants (for US only): TANIKAWA, Keizo [JP/JP]; Nissan Chemical Industries, Ltd., Central Research Institute, 722-1, Tsuboi-cho, Funabashi-shi, Chiba 274-0062 (JP). KAMIKAWAJI, Yoshimasa [JP/JP]; Nissan Chemical Industries, Ltd., Central Research Institute, 722-1, Tsuboi-cho, Funabashi-shi, Chiba 274-0062 (JP). HIROTSUKA, Mitsuaki [JP/JP]; Nissan Chemical Industries, Ltd., Central Research Institute, 722-1, Tsuboi-cho, Funabashi-shi, Chiba 274-0062 (JP). IWAMA, Takehisa [JP/JP]; Nissan Chemical Industries, Ltd., Seibutsukagaku Kenkyusho, No. 1470, Oaza-shiraoka, Shiraoka-machi, Minamisaitama-gun, Saitama 349-0218 (JP). YAMAMOTO,	Akiko [JP/JP]; Nissan Chemical Industries, Ltd., Seibutsukagaku Kenkyusho, No. 1470, Oaza-shiraoka, Shiraoka-machi, Minamisaitama-gun, Saitama 349-0218 (JP). FUJITA, Yoichiro [JP/JP]; Nissan Chemical Industries, Ltd., Seibutsukagaku Kenkyusho, No. 1470, Oaza-shiraoka, Shiraoka-machi, Minamisaitama-gun, Saitama 349-0218 (JP). (74) Agents: OGAWA, Toshiharu et al.; Torimoto Kogyo Building, 38, Kanda-Higashimatsushitacho, Chiyoda-ku, Tokyo 101-0042 (JP). (81) Designated States: AL, AU, CA, CN, CZ, HU, IL, KR, LT, LV, MK, MX, NO, NZ, RO, RU, SI, SK, UA, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>			
(54) Title: BENZIMIDAZOLE DERIVATIVE (I) (57) Abstract A benzimidazole derivative of formula (I) or its salt wherein A is a single bond or a C₁₋₂ alkylene group (this alkylene group may optionally be substituted by a C₁₋₄ alkyl group), R⁶ is a C₁₋₄ alkyl group (this alkyl group may optionally be substituted by a phenyl group), B is a C₂₋₃ alkylene group (this alkylene group may optionally be substituted by a C₁₋₄ alkyl group), X is an oxygen atom, a sulfur atom or NR⁷ (wherein R⁷ is a nitro group, a cyano group or a C₁₋₄ alkoxy group), each of R¹ and R² which are independent of each other, is a hydrogen atom, a halogen atom, a C₁₋₄ alkyl group or a C₁₋₄ alkoxy group, E is a C₁₋₂ alkylene group (this alkylene group may optionally be substituted by a C₁₋₄ alkyl group), R³ is a phenyl group (this phenyl group may optionally be substituted by a halogen atom, a C₁₋₄ alkyl group or a C₁₋₄ alkoxy group), a C₁₋₄ alkoxy group or a benzyloxy group, each of R⁴ and R⁵ which are independent of each other, is a C₁₋₄ alkyl group (this alkyl group may optionally be substituted by a phenyl group), D is a C₁₋₂ alkylene group (this alkylene group may optionally be substituted by a C₁₋₄ alkyl group), and Ar is a phenyl group (this phenyl group may optionally be substituted by a halogen atom, a C₁₋₄ alkyl group, a C₁₋₄ alkoxy group or a trifluoromethyl group).				

71416-175

1

DESCRIPTIONBENZIMIDAZOLE DERIVATIVE FOR TREATING ALLERGY-RELATED
DISEASETECHNICAL FIELD

5 The present invention relates to a novel
benzimidazole derivative having an antiallergic activity
and a drug containing it as an active ingredient.

BACKGROUND ART

10 In the treatment of type I allergy-related diseases
such as pollinosis, urticaria, atopic dermatitis,
allergic rhinitis and asthma, antihistamines and steroids
have heretofore been frequently used. However, problems
still remain with respect to the clinical usefulness
thereof. The above mentioned allergy-related diseases
15 are triggered by an immune reaction of a specific antigen
with IgE antibody and progress to a chronic state via
inflammation of the diseased portion or tissue damage.
It has been suggested that during this process, various
chemical mediators are mutually closely related to the
20 pathologic progress. Among them, histamine is believed
to be involved mainly at the initial stage of the
pathologic progress from the characteristics of its
pharmacological action. This is considered to be the
reason why a problem remains with respect to the clinical
25 usefulness of antihistamines. On the other hand,
steroids which are used primarily in severe cases, show
pharmacological activities to inhibit a series of

processes of immuno-inflammatory responses in various fashions and are believed to exhibit a high level of effectiveness. However, steroids have a problem of severe side effects, and there are many restrictions in their application to oral administration or repeated administration. Thus, in the field of treatment of type I allergy-related diseases, it is very much desired to develop a drug having a new mechanism for action and having a high level of effectiveness.

10 In recent years, it has been reported that substance P which is a neuropeptide, acts as a mediator to promote allergic symptoms and is deeply concerned in the inflammatory symptoms particularly in the chronic phase, (TIPS, 81, 24 (1987); Am. J. Respir. Crit. Care Med., 151, 613 (1995); J. Allergy Clin. Immunol., 92, 95 (1993)). Therefore, an antagonist of substance P is considered to be capable of effectively curing the allergic symptoms in the chronic phase (particularly the chronic inflammation).

20 Substance P is a member of the neurokinin family, and it is known that it is widely concerned in activation of macrophages or lymphocytes, and in immunity and inflammation as a regulatory factor for production of cytokine (IL1, TNF, IL6), and it causes inflammatory symptoms such as increase in vascular permeability, plasma leakage and secretory gland stimulation. Further, it functions as a transmitter of pain from peripheral to

central, and it controls the transmission system of dopamine and adrenaline in brain.

Accordingly, a substance P antagonist is considered to be effective not only as an antiallergic agent but
5 also as analgesics or psychomimetics.

Further, a drug having not only substance P antagonistic activities but also antihistamine activities, is considered to be effective for treatment of a wide range of allergic symptoms ranging from acute
10 phase to chronic phase and thus is expected to be a drug which has clinically high curing effects.

DISCLOSURE OF THE INVENTION

As a result of extensive studies, the present inventors have found that the benzimidazole derivatives
15 of the present invention have substance P antagonistic activities, and further that among the compounds of the present invention, many also have antihistamine activities.

Benzimidazoles having antihistamine activities have
20 already been disclosed in e.g. JP-A-59-199679, JP-A-58-79983, EP-232937B, EP144101B and U.S. Patent 4,219,559. However, the compounds of the present invention are not included in such disclosed benzimidazoles. Further, such prior art references disclose nothing about substance P
25 antagonistic activities.


Thus, it has been found that the compounds of the present invention are superior compounds as antiallergic

71416-175

4

agents, and they are not only useful as active ingredients for preventive or curing agents for pollinosis, urticaria, atopic dermatitis, allergic rhinitis and asthma etc., but also effective against
 5 other substance P related diseases, for example, eye diseases such as conjunctivitis and spring catarrh; inflammatory diseases such as chronic rheumatoid arthritis; pains such as migraine, headache, toothache and aches accompanying various diseases; gastrointestinal
 10 diseases such as ulcerative colitis and Crohn's disease; and mental diseases such as depression and dysthymia. The present invention has been accomplished on the basis of these discoveries.

The present invention provides a benzimidazole
 15 derivative of the formula (I) or its salt:



20 wherein A is a single bond or a C₁₋₂ alkylene group (this alkylene group may optionally be substituted by a C₁₋₄ alkyl group or a C₃₋₄ cycloalkyl group), R⁶ is a hydrogen atom or a C₁₋₄ alkyl group or a C₃₋₄ cycloalkyl group (each group may optionally be substituted by a phenyl group), B is a C₂₋₃
 25 alkylene group (this alkylene group may optionally be substituted by a C₁₋₄ alkyl group or a C₃₋₄ cycloalkyl group), X is an oxygen atom, a sulfur atom or NR⁷ (wherein R⁷ is a nitro group, a cyano group or a C₁₋₄ alkoxy group), each of R¹ and R² which are

71416-175

5

independent of each other, is hydrogen atom, a halogen atom, a C₁₋₄ alkyl group, or a C₃₋₄ cycloalkyl group or a C₁₋₄ alkoxy group, E is a C₁₋₂ alkylene group (this alkylene group may optionally be substituted by a C₁₋₄ alkyl group or a C₃₋₄ cycloalkyl group), R³ is a phenyl group (this phenyl group may optionally be substituted by a halogen atom, C₁₋₄ alkyl group, or a C₃₋₄ cycloalkyl group or a C₁₋₄ alkoxy group), a C₁₋₄ alkoxy group or a benzyloxy group, each of R⁴ and R⁵ which are independent of each other, is a hydrogen atom or a C₁₋₄ alkyl group or a C₃₋₄ cycloalkyl group (each group may optionally be substituted by a phenyl group), D is a C₁₋₂ alkylene group (this alkylene group may optionally be substituted by a C₁₋₄ alkyl group or a C₃₋₄ cycloalkyl group), and Ar is a phenyl group (this phenyl group may optionally be substituted by a halogen atom, a C₁₋₄ alkyl group, a C₃₋₄ cycloalkyl group, a C₁₋₄ alkoxy group or trifluoromethyl group), a process for its production and a pharmaceutical composition containing it as an active ingredient.

Now, the substituents relating to the compound of the present invention will be described.

In this specification, n means normal, i iso, s secondary, t tertiary, c cyclo, Me methyl, Et ethyl, Bu butyl, Ph phenyl, and Bn benzyl.

The C₁₋₂ alkylene group includes methylene and ethylene.

The C₂₋₃ alkylene group includes ethylene and trimethylene.

The C₁₋₄ alkyl group may be linear or branched and includes methyl, ethyl, n-propyl, i-propyl,

71416-175

6

n-butyl, i-butyl, s-butyl and t-butyl. The C₃₋₄ cycloalkyl group includes c-propyl and c-butyl.

The C₁₋₄ alkoxy group may be linear, branched or cyclic and includes methoxy, ethoxy, n-propoxy, i-propoxy, c-propoxy, n-butoxy, i-butoxy, s-butoxy, t-butoxy and c-butoxy.

The halogen atom includes fluorine, chlorine, bromine and iodine.

Now, A, B, D, E, Ar, X, R¹, R², R³, R⁴, R⁵ and R⁶ in the compound (I) of the present invention will be described in detail.

Specific examples of A include a single bond, CH₂, CHMe, CH₂CH₂ and CH₂CHMe, preferably a single bond and CH₂.

Specific examples of B include CH₂CH₂, CH₂CHMe, CHMeCH₂, CHMeCHMe, CH₂CH₂CH₂, CHMeCH₂CH₂, CH₂CHMeCH₂, CH₂CH₂CHMe, CHMeCHMeCH₂, CHMeCH₂CHMe, CH₂CHMeCHMe and CHMeCHMeCHMe, preferably CH₂CH₂ and CH₂CH₂CH₂.

Specific examples of D include CH₂, CHMe, CH₂CH₂ and CH₂CHMe, preferably CH₂, CHMe and CH₂CH₂.

Specific examples of E include CH₂, CHMe, CH₂CH₂ and CH₂CHMe, preferably CH₂ and CH₂CH₂.

Specific examples of Ar include phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-bromophenyl, 3-bromophenyl, 4-bromophenyl, 2-iodophenyl, 3-iodophenyl, 4-iodophenyl, 2-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 2-

- methylphenyl, 3-methylphenyl, 4-methylphenyl, 2-
 methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2,3-
 difluorophenyl, 2,4-difluorophenyl, 2,5-difluorophenyl,
 2,6-difluorophenyl, 3,4-difluorophenyl, 3,5-
 5 difluorophenyl, 2,3-dichlorophenyl, 2,4-dichlorophenyl,
 2,5-dichlorophenyl, 2,6-dichlorophenyl, 3,4-
 dichlorophenyl, 3,5-dichlorophenyl, 2,3-dibromophenyl,
 2,4-dibromophenyl, 2,5-dibromophenyl, 2,6-dibromophenyl,
 3,4-dibromophenyl, 3,5-dibromophenyl, 2,3-diiodophenyl,
 10 2,4-diiodophenyl, 2,5-diiodophenyl, 2,6-diiodophenyl,
 3,4-diiodophenyl, 3,5-diiodophenyl, 2,3-
 bis(trifluoromethyl)phenyl, 2,4-
 bis(trifluoromethyl)phenyl, 2,5-
 bis(trifluoromethyl)phenyl, 2,6-
 15 bis(trifluoromethyl)phenyl, 3,4-
 bis(trifluoromethyl)phenyl, 3,5-
 bis(trifluoromethyl)phenyl, 2,3-dimethylphenyl, 2,4-
 dimethylphenyl, 2,5-dimethylphenyl, 2,6-dimethylphenyl,
 3,4-dimethylphenyl, 3,5-dimethylphenyl, 2,3-
 20 dimethoxyphenyl, 2,4-dimethoxyphenyl, 2,5-
 dimethoxyphenyl, 2,6-dimethoxyphenyl, 3,4-
 dimethoxyphenyl, 3,5-dimethoxyphenyl and 2-chloro-5-
 trifluoromethylphenyl, preferably phenyl, 2-chlorophenyl,
 2-methoxyphenyl, 3,5-dimethylphenyl, 3,5-
 25 bis(trifluoromethyl)phenyl, 3,5-dimethoxyphenyl, 2,5-
 dichlorophenyl and 2-chloro-5-trifluoromethylphenyl.

Specific examples of X include an oxygen atom, a

sulfur atom, N-CN, N-NO₂, N-OMe, N-OEt and N-OBu, preferably an oxygen atom.

Specific examples of each of R¹ and R² include a hydrogen atom, fluorine, chlorine, bromine, iodine, methyl, ethyl, n-propyl, i-propyl, c-propyl, n-butyl, i-butyl, s-butyl, t-butyl, c-butyl, methoxy, ethoxy, n-propoxy, i-propoxy, c-propoxy, n-butoxy, i-butoxy, s-butoxy, t-butoxy and c-butoxy, preferably a hydrogen atom.

Specific examples of R³ include phenyl, 4-fluorophenyl, 4-chlorophenyl, methoxy, ethoxy and benzyloxy, preferably 4-fluorophenyl and ethoxy.

Specific examples of each of R⁴ and R⁵ include a hydrogen atom, methyl, ethyl, n-propyl, i-propyl, c-propyl, n-butyl, i-butyl, s-butyl, t-butyl, c-butyl and benzyl, preferably a hydrogen atom, methyl and benzyl.

Specific examples of R⁶ include a hydrogen atom, methyl, ethyl, n-propyl, i-propyl, c-propyl, n-butyl, i-butyl, s-butyl, t-butyl, c-butyl and benzyl, preferably a hydrogen atom, methyl and benzyl.

The following compounds may be mentioned as preferred compounds among the compounds of the formula (I) of the present invention.

(1) The compound of the formula (I) or its salt, wherein A is a single bond, CH₂, CHMe, CH₂CH₂ or CH₂CHMe, B is CH₂CH₂, CH₂CHMe, CHMeCH₂, CHMeCHMe, CH₂CH₂CH₂, CHMeCH₂CH₂, CH₂CHMeCH₂, CH₂CH₂CHMe, CHMeCHMeCH₂,

CHMeCH₂CHMe, CH₂CHMeCHMe or CHMeCHMeCHMe, D is CH₂, CHMe, CH₂CH₂ or CH₂CHMe, E is CH₂, CHMe, CH₂CH₂ or CH₂CHMe, Ar is phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-bromophenyl, 3-bromophenyl, 4-bromophenyl, 2-iodophenyl, 3-iodophenyl, 4-iodophenyl, 2-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2,3-difluorophenyl, 2,4-difluorophenyl, 2,5-difluorophenyl, 2,6-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2,3-dichlorophenyl, 2,4-dichlorophenyl, 2,5-dichlorophenyl, 2,6-dichlorophenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl, 2,3-dibromophenyl, 2,4-dibromophenyl, 2,5-dibromophenyl, 2,6-dibromophenyl, 3,4-dibromophenyl, 3,5-dibromophenyl, 2,3-diiodophenyl, 2,4-diiodophenyl, 2,5-diiodophenyl, 2,6-diiodophenyl, 3,4-diiodophenyl, 3,5-diiodophenyl, 2,3-bis(trifluoromethyl)phenyl, 2,4-bis(trifluoromethyl)phenyl, 2,5-bis(trifluoromethyl)phenyl, 2,6-bis(trifluoromethyl)phenyl, 3,4-bis(trifluoromethyl)phenyl, 3,5-bis(trifluoromethyl)phenyl, 2,3-dimethylphenyl, 2,4-dimethylphenyl, 2,5-dimethylphenyl, 2,6-dimethylphenyl, 3,4-dimethylphenyl, 3,5-dimethylphenyl, 2,3-dimethoxyphenyl, 2,4-dimethoxyphenyl, 2,5-

dimethoxyphenyl, 2,6-dimethoxyphenyl, 3,4-dimethoxyphenyl, 3,5-dimethoxyphenyl or 2-chloro-5-trifluoromethylphenyl, X is an oxygen atom, a sulfur atom, N-CN, N-NO₂, N-OMe, N-OEt or N-OBu, each of R¹ and
5 R² is a hydrogen atom, fluorine, chlorine, bromine, iodine, methyl, ethyl, n-propyl, i-propyl, c-propyl, n-butyl, i-butyl, s-butyl, t-butyl, c-butyl, methoxy, ethoxy, n-propoxy, i-propoxy, c-propoxy, n-butoxy, i-butoxy, s-butoxy, t-butoxy or c-butoxy, R³ is phenyl, 4-
10 fluorophenyl, 4-chlorophenyl, methoxy, ethoxy or benzyloxy, each of R⁴ and R⁵ is a hydrogen atom, methyl, ethyl, n-propyl, i-propyl, c-propyl, n-butyl, i-butyl, s-butyl, t-butyl, c-butyl or benzyl, and R⁶ is a hydrogen atom, methyl, ethyl, n-propyl, i-propyl, c-propyl, n-
15 butyl, i-butyl, s-butyl, t-butyl, c-butyl or benzyl.

(2) The compound or its salt according to the above item (1), wherein X is an oxygen atom.

(3) The compound or its salt according to the above item (2), wherein each of R¹ and R² is a hydrogen atom.

20 (4) The compound of the formula (I) or its salt, wherein A is a single bond or CH₂, B is CH₂CH₂ or CH₂CH₂CH₂, D is CH₂, CHMe or CH₂CH₂, E is CH₂ or CH₂CH₂, Ar is phenyl, 2-chlorophenyl, 2-methoxyphenyl, 3,5-dimethylphenyl, 3,5-bis(trifluoromethyl)phenyl, 3,5-
25 dimethoxyphenyl, 2,5-dichlorophenyl or 2-chloro-5-trifluoromethylphenyl, X is an oxygen atom, each of R¹ and R² is a hydrogen atom, R³ is 4-fluorophenyl or


ethoxy, each of R^4 and R^5 is a hydrogen atom, methyl or benzyl, and R^6 is a hydrogen atom, methyl or benzyl.

(5) The compound or its salt according to the above item (4), wherein E is CH_2 , and R^3 is a 4-fluorophenyl group.

(6) The compound or its salt according to the above item (5), wherein Ar is 3,5-bis(trifluoromethyl)phenyl.


Now, typical compounds among benzimidazole derivatives of the formula (Ia) as the compounds of the present invention will be presented in Table 1, but it should be understood that the present invention is by no means restricted to such specific compounds.

In Table 1, Q1 to Q43 represent the groups of the following formulae:




Q25	Q26	Q27	Q28
Q29	Q30	Q31	Q32
			-CH2·CH2-
Q33	Q34	Q35	Q36
-CHMeCH2-	-CH2CHMe-	-CHMeCHMe-	-CH2CH2CH2-
Q37	Q38	Q39	
-CHMeCH2CH2-	-CH2CHMeCH2-	-CH2CH2CHMe-	
Q40	Q41	Q42	
-CHMeCHMeCH2-	-CHMeCH2CHMe-	-CH2CHMeCHMe-	
Q43			
-CHMeCHMeCHMe-			

Further, M in the Table has the following meaning:



wherein R⁴, R⁵ and X are as defined above.

Table 1



A	B	D	E	M	Ar	R ¹	R ²	R ³	R ⁶
—	Q32	CH ₂	CH ₂	Q10	Q1	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q10	Q2	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q10	Q3	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q10	Q4	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q10	Q5	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q10	Q7	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q10	Q8	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q10	Q1	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q10	Q2	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q10	Q3	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q10	Q4	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q10	Q5	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q10	Q7	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q10	Q8	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q10	Q1	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q10	Q2	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q10	Q3	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q10	Q4	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q10	Q5	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q10	Q7	H	H	Q3	Me

Table 1 (continued)

A	B	D	E	M	Ar	R ¹	R ²	R ³	R ⁶
—	Q36	CH ₂	CH ₂	Q10	Q8	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q10	Q1	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q10	Q2	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q10	Q3	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q10	Q4	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q10	Q5	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q10	Q7	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q10	Q8	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q10	Q1	H	H	Ph	Me
—	Q32	CH ₂	CH ₂	Q10	Q2	H	H	Ph	Me
—	Q32	CH ₂	CH ₂	Q10	Q3	H	H	Ph	Me
—	Q32	CH ₂	CH ₂	Q10	Q4	H	H	Ph	Me
—	Q32	CH ₂	CH ₂	Q10	Q5	H	H	Ph	Me
—	Q32	CH ₂	CH ₂	Q10	Q6	H	H	Ph	Me
—	Q32	CH ₂	CH ₂	Q10	Q7	H	H	Ph	Me
—	Q32	CH ₂	CH ₂	Q10	Q8	H	H	Ph	Me
CH ₂	Q32	CH ₂	CH ₂	Q10	Q1	H	H	Ph	Me
CH ₂	Q32	CH ₂	CH ₂	Q10	Q2	H	H	Ph	Me
CH ₂	Q32	CH ₂	CH ₂	Q10	Q3	H	H	Ph	Me
CH ₂	Q32	CH ₂	CH ₂	Q10	Q4	H	H	Ph	Me
CH ₂	Q32	CH ₂	CH ₂	Q10	Q5	H	H	Ph	Me
CH ₂	Q32	CH ₂	CH ₂	Q10	Q6	H	H	Ph	Me

Table 1 (continued)

A	B	D	E	M	Ar	R ¹	R ²	R ³	R ⁶
CH ₂	Q32	CH ₂	CH ₂	Q10	Q7	H	H	Ph	Me
CH ₂	Q32	CH ₂	CH ₂	Q10	Q8	H	H	Ph	Me
—	Q36	CH ₂	CH ₂	Q10	Q1	H	H	Ph	Me
—	Q36	CH ₂	CH ₂	Q10	Q2	H	H	Ph	Me
—	Q36	CH ₂	CH ₂	Q10	Q3	H	H	Ph	Me
—	Q36	CH ₂	CH ₂	Q10	Q4	H	H	Ph	Me
—	Q36	CH ₂	CH ₂	Q10	Q5	H	H	Ph	Me
—	Q36	CH ₂	CH ₂	Q10	Q6	H	H	Ph	Me
—	Q36	CH ₂	CH ₂	Q10	Q7	H	H	Ph	Me
—	Q36	CH ₂	CH ₂	Q10	Q8	H	H	Ph	Me
CH ₂	Q36	CH ₂	CH ₂	Q10	Q1	H	H	Ph	Me
CH ₂	Q36	CH ₂	CH ₂	Q10	Q2	H	H	Ph	Me
CH ₂	Q36	CH ₂	CH ₂	Q10	Q3	H	H	Ph	Me
CH ₂	Q36	CH ₂	CH ₂	Q10	Q4	H	H	Ph	Me
CH ₂	Q36	CH ₂	CH ₂	Q10	Q5	H	H	Ph	Me
CH ₂	Q36	CH ₂	CH ₂	Q10	Q6	H	H	Ph	Me
CH ₂	Q36	CH ₂	CH ₂	Q10	Q7	H	H	Ph	Me
CH ₂	Q36	CH ₂	CH ₂	Q10	Q8	H	H	Ph	Me
—	Q32	CH ₂	CH ₂	Q10	Q1	H	H	Q4	Me
—	Q32	CH ₂	CH ₂	Q10	Q2	H	H	Q4	Me
—	Q32	CH ₂	CH ₂	Q10	Q3	H	H	Q4	Me
—	Q32	CH ₂	CH ₂	Q10	Q4	H	H	Q4	Me
—	Q32	CH ₂	CH ₂	Q10	Q5	H	H	Q4	Me

Table 1 (continued)

A	B	D	E	M	Ar	R ¹	R ²	R ³	R ⁶
—	Q32	CH ₂	CH ₂	Q10	Q6	H	H	Q4	Me
—	Q32	CH ₂	CH ₂	Q10	Q7	H	H	Q4	Me
—	Q32	CH ₂	CH ₂	Q10	Q8	H	H	Q4	Me
CH ₂	Q32	CH ₂	CH ₂	Q10	Q1	H	H	Q4	Me
CH ₂	Q32	CH ₂	CH ₂	Q10	Q2	H	H	Q4	Me
CH ₂	Q32	CH ₂	CH ₂	Q10	Q3	H	H	Q4	Me
CH ₂	Q32	CH ₂	CH ₂	Q10	Q4	H	H	Q4	Me
CH ₂	Q32	CH ₂	CH ₂	Q10	Q5	H	H	Q4	Me
CH ₂	Q32	CH ₂	CH ₂	Q10	Q6	H	H	Q4	Me
CH ₂	Q32	CH ₂	CH ₂	Q10	Q7	H	H	Q4	Me
CH ₂	Q32	CH ₂	CH ₂	Q10	Q8	H	H	Q4	Me
—	Q36	CH ₂	CH ₂	Q10	Q1	H	H	Q4	Me
—	Q36	CH ₂	CH ₂	Q10	Q2	H	H	Q4	Me
—	Q36	CH ₂	CH ₂	Q10	Q3	H	H	Q4	Me
—	Q36	CH ₂	CH ₂	Q10	Q4	H	H	Q4	Me
—	Q36	CH ₂	CH ₂	Q10	Q5	H	H	Q4	Me
—	Q36	CH ₂	CH ₂	Q10	Q6	H	H	Q4	Me
—	Q36	CH ₂	CH ₂	Q10	Q7	H	H	Q4	Me
—	Q36	CH ₂	CH ₂	Q10	Q8	H	H	Q4	Me
CH ₂	Q36	CH ₂	CH ₂	Q10	Q1	H	H	Q4	Me
CH ₂	Q36	CH ₂	CH ₂	Q10	Q2	H	H	Q4	Me
CH ₂	Q36	CH ₂	CH ₂	Q10	Q3	H	H	Q4	Me
CH ₂	Q36	CH ₂	CH ₂	Q10	Q4	H	H	Q4	Me

Table 1 (continued)

A	B	D	E	M	Ar	R ¹	R ²	R ³	R ⁶
CH ₂	Q36	CH ₂	CH ₂	Q10	Q5	H	H	Q4	Me
CH ₂	Q36	CH ₂	CH ₂	Q10	Q6	H	H	Q4	Me
CH ₂	Q36	CH ₂	CH ₂	Q10	Q7	H	H	Q4	Me
CH ₂	Q36	CH ₂	CH ₂	Q10	Q8	H	H	Q4	Me
—	Q32	CH ₂	CH ₂	Q10	Q1	H	H	Q3	H
—	Q32	CH ₂	CH ₂	Q10	Q2	H	H	Q3	H
—	Q32	CH ₂	CH ₂	Q10	Q3	H	H	Q3	H
—	Q32	CH ₂	CH ₂	Q10	Q4	H	H	Q3	H
—	Q32	CH ₂	CH ₂	Q10	Q5	H	H	Q3	H
—	Q32	CH ₂	CH ₂	Q10	Q6	H	H	Q3	H
—	Q32	CH ₂	CH ₂	Q10	Q7	H	H	Q3	H
—	Q32	CH ₂	CH ₂	Q10	Q8	H	H	Q3	H
CH ₂	Q32	CH ₂	CH ₂	Q10	Q1	H	H	Q3	H
CH ₂	Q32	CH ₂	CH ₂	Q10	Q2	H	H	Q3	H
CH ₂	Q32	CH ₂	CH ₂	Q10	Q3	H	H	Q3	H
CH ₂	Q32	CH ₂	CH ₂	Q10	Q4	H	H	Q3	H
CH ₂	Q32	CH ₂	CH ₂	Q10	Q5	H	H	Q3	H
CH ₂	Q32	CH ₂	CH ₂	Q10	Q6	H	H	Q3	H
CH ₂	Q32	CH ₂	CH ₂	Q10	Q7	H	H	Q3	H
CH ₂	Q32	CH ₂	CH ₂	Q10	Q8	H	H	Q3	H
—	Q36	CH ₂	CH ₂	Q10	Q1	H	H	Q3	H
—	Q36	CH ₂	CH ₂	Q10	Q2	H	H	Q3	H
—	Q36	CH ₂	CH ₂	Q10	Q3	H	H	Q3	H

Table 1 (continued)

A	B	D	E	M	Ar	R ¹	R ²	R ³	R ⁶
—	Q36	CH ₂	CH ₂	Q10	Q4	H	H	Q3	H
—	Q36	CH ₂	CH ₂	Q10	Q5	H	H	Q3	H
—	Q36	CH ₂	CH ₂	Q10	Q6	H	H	Q3	H
—	Q36	CH ₂	CH ₂	Q10	Q7	H	H	Q3	H
—	Q36	CH ₂	CH ₂	Q10	Q8	H	H	Q3	H
CH ₂	Q36	CH ₂	CH ₂	Q10	Q1	H	H	Q3	H
CH ₂	Q36	CH ₂	CH ₂	Q10	Q2	H	H	Q3	H
CH ₂	Q36	CH ₂	CH ₂	Q10	Q3	H	H	Q3	H
CH ₂	Q36	CH ₂	CH ₂	Q10	Q4	H	H	Q3	H
CH ₂	Q36	CH ₂	CH ₂	Q10	Q5	H	H	Q3	H
CH ₂	Q36	CH ₂	CH ₂	Q10	Q6	H	H	Q3	H
CH ₂	Q36	CH ₂	CH ₂	Q10	Q7	H	H	Q3	H
CH ₂	Q36	CH ₂	CH ₂	Q10	Q8	H	H	Q3	H
—	Q32	CH ₂	CH ₂	Q9	Q1	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q9	Q2	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q9	Q3	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q9	Q4	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q9	Q5	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q9	Q6	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q9	Q7	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q9	Q8	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q9	Q1	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q9	Q2	H	H	Q3	Me

Table 1 (continued)

A	B	D	E	M	Ar	R ¹	R ²	R ³	R ⁶
CH ₂	Q32	CH ₂	CH ₂	Q9	Q3	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q9	Q4	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q9	Q5	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q9	Q6	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q9	Q7	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q9	Q8	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q9	Q1	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q9	Q2	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q9	Q3	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q9	Q4	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q9	Q5	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q9	Q6	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q9	Q7	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q9	Q8	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q9	Q1	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q9	Q2	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q9	Q3	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q9	Q4	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q9	Q5	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q9	Q6	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q9	Q7	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q9	Q8	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q11	Q1	H	H	Q3	Me

Table 1 (continued)

A	B	D	E	M	Ar	R ¹	R ²	R ³	R ⁶
—	Q32	CH ₂	CH ₂	Q11	Q2	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q11	Q3	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q11	Q4	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q11	Q5	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q11	Q6	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q11	Q7	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q11	Q8	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q11	Q1	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q11	Q2	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q11	Q3	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q11	Q4	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q11	Q5	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q11	Q6	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q11	Q7	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q11	Q8	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q11	Q1	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q11	Q2	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q11	Q3	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q11	Q4	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q11	Q5	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q11	Q6	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q11	Q7	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q11	Q8	H	H	Q3	Me

Table 1 (continued)

A	B	D	E	M	Ar	R ¹	R ²	R ³	R ⁶
CH ₂	Q36	CH ₂	CH ₂	Q11	Q1	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q11	Q2	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q11	Q3	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q11	Q4	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q11	Q5	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q11	Q6	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q11	Q7	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q11	Q8	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q12	Q1	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q12	Q2	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q12	Q3	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q12	Q4	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q12	Q5	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q12	Q6	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q12	Q7	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q12	Q8	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q12	Q1	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q12	Q2	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q12	Q3	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q12	Q4	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q12	Q5	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q12	Q6	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q12	Q7	H	H	Q3	Me

Table 1 (continued)

A	B	D	E	M	Ar	R ¹	R ²	R ³	R ⁶
CH ₂	Q32	CH ₂	CH ₂	Q12	Q8	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q12	Q1	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q12	Q2	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q12	Q3	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q12	Q4	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q12	Q5	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q12	Q6	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q12	Q7	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q12	Q8	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q12	Q1	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q12	Q2	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q12	Q3	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q12	Q4	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q12	Q5	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q12	Q6	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q12	Q7	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q12	Q8	H	H	Q3	Me
—	Q32	CHMe	CH ₂	Q10	Q1	H	H	Q3	Me
—	Q32	CHMe	CH ₂	Q10	Q2	H	H	Q3	Me
—	Q32	CHMe	CH ₂	Q10	Q3	H	H	Q3	Me
—	Q32	CHMe	CH ₂	Q10	Q4	H	H	Q3	Me
—	Q32	CHMe	CH ₂	Q10	Q5	H	H	Q3	Me
—	Q32	CHMe	CH ₂	Q10	Q6	H	H	Q3	Me

Table 1 (continued)

A	B	D	E	M	Ar	R ¹	R ²	R ³	R ⁶
—	Q32	CHMe	CH ₂	Q10	Q7	H	H	Q3	Me
—	Q32	CHMe	CH ₂	Q10	Q8	H	H	Q3	Me
CH ₂	Q32	CHMe	CH ₂	Q10	Q1	H	H	Q3	Me
CH ₂	Q32	CHMe	CH ₂	Q10	Q2	H	H	Q3	Me
CH ₂	Q32	CHMe	CH ₂	Q10	Q3	H	H	Q3	Me
CH ₂	Q32	CHMe	CH ₂	Q10	Q4	H	H	Q3	Me
CH ₂	Q32	CHMe	CH ₂	Q10	Q5	H	H	Q3	Me
CH ₂	Q32	CHMe	CH ₂	Q10	Q6	H	H	Q3	Me
CH ₂	Q32	CHMe	CH ₂	Q10	Q7	H	H	Q3	Me
CH ₂	Q32	CHMe	CH ₂	Q10	Q8	H	H	Q3	Me
—	Q36	CHMe	CH ₂	Q10	Q1	H	H	Q3	Me
—	Q36	CHMe	CH ₂	Q10	Q2	H	H	Q3	Me
—	Q36	CHMe	CH ₂	Q10	Q3	H	H	Q3	Me
—	Q36	CHMe	CH ₂	Q10	Q4	H	H	Q3	Me
—	Q36	CHMe	CH ₂	Q10	Q5	H	H	Q3	Me
—	Q36	CHMe	CH ₂	Q10	Q6	H	H	Q3	Me
—	Q36	CHMe	CH ₂	Q10	Q7	H	H	Q3	Me
—	Q36	CHMe	CH ₂	Q10	Q8	H	H	Q3	Me
CH ₂	Q36	CHMe	CH ₂	Q10	Q1	H	H	Q3	Me
CH ₂	Q36	CHMe	CH ₂	Q10	Q2	H	H	Q3	Me
CH ₂	Q36	CHMe	CH ₂	Q10	Q3	H	H	Q3	Me
CH ₂	Q36	CHMe	CH ₂	Q10	Q4	H	H	Q3	Me
CH ₂	Q36	CHMe	CH ₂	Q10	Q5	H	H	Q3	Me

Table 1 (continued)

A	B	D	E	M	Ar	R ¹	R ²	R ³	R ⁶
CH ₂	Q36	CHMe	CH ₂	Q10	Q6	H	H	Q3	Me
CH ₂	Q36	CHMe	CH ₂	Q10	Q7	H	H	Q3	Me
CH ₂	Q36	CHMe	CH ₂	Q10	Q8	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q13	Q1	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q13	Q2	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q13	Q6	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q13	Q1	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q13	Q2	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q13	Q6	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q13	Q1	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q13	Q2	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q13	Q6	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q13	Q1	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q13	Q2	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q13	Q6	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q14	Q1	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q14	Q2	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q14	Q6	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q14	Q1	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q14	Q2	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q14	Q6	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q14	Q1	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q14	Q2	H	H	Q3	Me

Table 1 (continued)

A	B	D	E	M	Ar	R ¹	R ²	R ³	R ⁶
—	Q36	CH ₂	CH ₂	Q14	Q6	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q14	Q1	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q14	Q2	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q14	Q6	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q15	Q1	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q15	Q2	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q15	Q6	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q15	Q1	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q15	Q2	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q15	Q6	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q15	Q1	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q15	Q2	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q15	Q6	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q15	Q1	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q15	Q2	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q15	Q6	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q16	Q6	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q16	Q6	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q16	Q6	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q16	Q6	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q17	Q6	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q17	Q6	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q17	Q6	H	H	Q3	Me

Table 1 (continued)

A	B	D	E	M	Ar	R ¹	R ²	R ³	R ⁶
CH ₂	Q36	CH ₂	CH ₂	Q17	Q6	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q18	Q6	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q18	Q6	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q18	Q6	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q18	Q6	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q19	Q6	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q19	Q6	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q19	Q6	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q19	Q6	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q20	Q6	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q20	Q6	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q20	Q6	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q20	Q6	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q21	Q6	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q21	Q6	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q21	Q6	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q21	Q6	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q22	Q6	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q22	Q6	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q22	Q6	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q22	Q6	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q23	Q6	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q23	Q6	H	H	Q3	Me

Table 1 (continued)

A	B	D	E	M	Ar	R ¹	R ²	R ³	R ⁶
—	Q36	CH ₂	CH ₂	Q23	Q6	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q23	Q6	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q24	Q6	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q24	Q6	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q24	Q6	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q24	Q6	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q25	Q6	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q25	Q6	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q25	Q6	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q25	Q6	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q26	Q6	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q26	Q6	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q26	Q6	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q26	Q6	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q27	Q6	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q27	Q6	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q27	Q6	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q27	Q6	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q28	Q6	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q28	Q6	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q28	Q6	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q28	Q6	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q29	Q6	H	H	Q3	Me

Table 1 (continued)

A	B	D	E	M	Ar	R ¹	R ²	R ³	R ⁶
CH ₂	Q32	CH ₂	CH ₂	Q29	Q6	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q29	Q6	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q29	Q6	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q30	Q6	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q30	Q6	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q30	Q6	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q30	Q6	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q31	Q6	H	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q31	Q6	H	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q31	Q6	H	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q31	Q6	H	H	Q3	Me
—	Q33	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Me
CH ₂	Q33	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Me
—	Q34	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Me
CH ₂	Q34	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Me
—	Q35	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Me
CH ₂	Q35	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Me
—	Q37	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Me
CH ₂	Q37	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Me
—	Q38	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Me
CH ₂	Q38	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Me
—	Q39	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Me
CH ₂	Q39	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Me

Table 1 (continued)

A	B	D	E	M	Ar	R ¹	R ²	R ³	R ⁶
—	Q40	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Me
CH ₂	Q40	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Me
—	Q41	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Me
CH ₂	Q41	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Me
—	Q42	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Me
CH ₂	Q42	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Me
—	Q43	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Me
CH ₂	Q43	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Me
Q32	Q32	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Me
CHMe	Q32	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Me
Q32	Q36	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Me
CHMe	Q36	CH ₂	CH ₂	Q1	Q6	H	H	Q3	Me
Q32	Q33	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Me
CHMe	Q33	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Me
Q32	Q34	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Me
CHMe	Q34	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Me
Q32	Q35	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Me
CHMe	Q35	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Me
Q32	Q37	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Me
CHMe	Q37	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Me
Q32	Q38	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Me
CHMe	Q38	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Me
Q32	Q39	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Me

Table 1 (continued)

A	B	D	E	M	Ar	R ¹	R ²	R ³	R ⁶
CHMe	Q39	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Me
Q32	Q40	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Me
CHMe	Q40	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Me
Q32	Q41	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Me
CHMe	Q41	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Me
Q32	Q42	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Me
CHMe	Q42	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Me
Q32	Q43	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Me
CHMe	Q43	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Bn
CH ₂	Q32	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Bn
—	Q36	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Bn
CH ₂	Q36	CH ₂	CH ₂	Q10	Q6	H	H	Q3	Bn
—	Q32	Q32	CH ₂	Q10	Q6	H	H	Q3	Me
CH ₂	Q32	Q32	CH ₂	Q10	Q6	H	H	Q3	Me
—	Q36	Q32	CH ₂	Q10	Q6	H	H	Q3	Me
CH ₂	Q36	Q32	CH ₂	Q10	Q6	H	H	Q3	Me
—	Q32	CH ₂	Q32	Q10	Q6	H	H	OMe	Me
CH ₂	Q32	CH ₂	Q32	Q10	Q6	H	H	OMe	Me
—	Q36	CH ₂	Q32	Q10	Q6	H	H	Ome	Me
CH ₂	Q36	CH ₂	Q32	Q10	Q6	H	H	OMe	Me
—	Q32	CH ₂	Q32	Q10	Q6	H	H	OBt	Me
CH ₂	Q32	CH ₂	Q32	Q10	Q6	H	H	OBt	Me

Table 1 (continued)

A	B	D	E	M	Ar	R ¹	R ²	R ³	R ⁶
—	Q36	CH ₂	Q32	Q10	Q6	H	H	OEt	Me
CH ₂	Q36	CH ₂	Q32	Q10	Q6	H	H	OEt	Me
—	Q32	CH ₂	CH ₂	Q10	Q6	5-F	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q10	Q6	5-F	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q10	Q6	5-F	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q10	Q6	5-F	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q10	Q6	6-F	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q10	Q6	6-F	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q10	Q6	6-F	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q10	Q6	6-F	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q10	Q6	5-Cl	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q10	Q6	5-Cl	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q10	Q6	5-Cl	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q10	Q6	5-Cl	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q10	Q6	6-Cl	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q10	Q6	6-Cl	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q10	Q6	6-Cl	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q10	Q6	6-Cl	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q10	Q6	5-Br	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q10	Q6	5-Br	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q10	Q6	5-Br	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q10	Q6	5-Br	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q10	Q6	6-Br	H	Q3	Me

Table 1 (continued)

A	B	D	E	M	Ar	R ¹	R ²	R ³	R ⁶
CH ₂	Q32	CH ₂	CH ₂	Q10	Q6	6-Br	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q10	Q6	6-Br	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q10	Q6	6-Br	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q10	Q6	5-F	6-F	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q10	Q6	5-F	6-F	Q3	Me
—	Q36	CH ₂	CH ₂	Q10	Q6	5-F	6-F	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q10	Q6	5-F	6-F	Q3	Me
—	Q32	CH ₂	CH ₂	Q10	Q6	5-Cl	6-Cl	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q10	Q6	5-Cl	6-Cl	Q3	Me
—	Q36	CH ₂	CH ₂	Q10	Q6	5-Cl	6-Cl	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q10	Q6	5-Cl	6-Cl	Q3	Me
—	Q32	CH ₂	CH ₂	Q10	Q6	5-Br	6-Br	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q10	Q6	5-Br	6-Br	Q3	Me
—	Q36	CH ₂	CH ₂	Q10	Q6	5-Br	6-Br	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q10	Q6	5-Br	6-Br	Q3	Me
—	Q32	CH ₂	CH ₂	Q10	Q6	5-Me	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q10	Q6	5-Me	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q10	Q6	5-Me	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q10	Q6	5-Me	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q10	Q6	6-Me	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q10	Q6	6-Me	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q10	Q6	6-Me	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q10	Q6	6-Me	H	Q3	Me

Table 1 (continued)


A	B	D	E	M	Ar	R ¹	R ²	R ³	R ⁶
—	Q32	CH ₂	CH ₂	Q10	Q6	5-OMe	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q10	Q6	5-OMe	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q10	Q6	5-OMe	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q10	Q6	5-OMe	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q10	Q6	6-OMe	H	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q10	Q6	6-OMe	H	Q3	Me
—	Q36	CH ₂	CH ₂	Q10	Q6	6-OMe	H	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q10	Q6	6-OMe	H	Q3	Me
—	Q32	CH ₂	CH ₂	Q10	Q6	5-Me	6-Me	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q10	Q6	5-Me	6-Me	Q3	Me
—	Q36	CH ₂	CH ₂	Q10	Q6	5-Me	6-Me	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q10	Q6	5-Me	6-Me	Q3	Me
—	Q32	CH ₂	CH ₂	Q10	Q6	5-OMe	6-OMe	Q3	Me
CH ₂	Q32	CH ₂	CH ₂	Q10	Q6	5-OMe	6-OMe	Q3	Me
—	Q36	CH ₂	CH ₂	Q10	Q6	5-OMe	6-OMe	Q3	Me
CH ₂	Q36	CH ₂	CH ₂	Q10	Q6	5-OMe	6-OMe	Q3	Me

The compound of the formula (I) of the present invention can be used for the purpose of the present invention either in its free form or in the form of a pharmacologically acceptable salt. Such an acid addition
 5 salt may, for example, be a mineral acid salt (such as a hydrochloride, a hydrobromide, a sulfate, a hydrogen sulfate, a nitrate, a phosphate, a hydrogen phosphate or a dihydrogen phosphate), an organic acid salt (such as a formate, an acetate, a propionate, a succinate, a
 10 malonate, an oxalate, a maleate, a fumarate, a malate, a citrate, a tartarate, a lactate, a glutamate, an asparatate, a picrate or a carbonate), or a sulfonate (such as a methanesulfonate, a benzenesulfonate or a toluenesulfonate).

15 Now, processes for the production of the compounds of the present invention will be described.

The benzimidazole derivatives of the formula (I) as the compounds of the present invention can be produced by processes represented by the following reaction schemes
 20 (1) to (7).

Reaction scheme (1)



wherein A, B, D, E, X, Ar, X, R¹, R², R³, R⁴, R⁵ and R⁵ are as defined above, and Y is a leaving group such as a halogen atom such as a chlorine atom, a bromine atom or an iodine atom, a methanesulfonyloxy group, a p-toluenesulfonyloxy group, or a trifluoromethanesulfonyloxy group.

The reaction scheme (1) is a process for producing the compound of the present invention by reacting a compound (IIa) with a compound (IIIa).

10 This reaction is carried out usually in the presence or absence of an inorganic base or an organic base.

The inorganic base includes metal carbonates such as potassium carbonate, sodium carbonate, lithium carbonate, potassium bicarbonate and sodium bicarbonate, metal hydroxides such as lithium hydroxide, sodium hydroxide and potassium hydroxide, metal hydrides such as sodium hydride, potassium hydride and n-butyl lithium, metal alkoxides such as sodium methoxide, sodium ethoxide and potassium t-butoxide, and metal amides such as sodium amide, lithium diisopropylamide, lithium hexamethyldisilazide, sodium hexamethyldisilazide and 2,2,6,6-tetramethylpiperidide.

The organic base includes, for example, trimethylamine, triethylamine, pyridine and diisopropylethylamine.


The solvent for the reaction may be any solvent so

long as it will not be involved in the reaction, and it may, for example, be a hydrocarbon type solvent such as benzene, toluene or hexane, an ether type solvent such as tetrahydrofuran, diethyl ether or 1,4-dioxane, an amide
 5 type solvent such as formamide, N,N-dimethylacetamide, N,N-dimethylformamide or N-methylpyrrolidone, an alcohol type solvent such as methanol, ethanol or propanol, a halogen type solvent such as chloroform, methylene chloride or ethylene chloride, other solvent such as
 10 acetonitrile or dimethylsulfoxide, water, or a solvent mixture thereof. However, the reaction may be carried out in the absence of a solvent.

The temperature for the reaction may be within a range of from -78°C to the boiling point of the solvent
 15 used for the reaction.

The molar ratio of the starting materials can optionally be set, but the compound (IIa) may be used in an amount of from 0.8 to 10 mols per mol of the compound (IIa).

20 Reaction scheme (2)




wherein A, B, D, E, X, Y, Ar, R¹, R², R³, R⁴, R⁵ and R⁶ are as defined above.

The reaction scheme (2) is a process for producing the compound of the present invention by reacting a
5 compound (IIb) with a compound (IIIb).

This reaction can be carried out under conditions similar to reaction scheme (1).

The molar ratio of the starting materials can optionally be set, but the compound (IIb) may be used in
10 an amount of from 0.8 to 10 mols per mol of the compound (IIIb).

Reaction scheme (3)



20 wherein A, B, D, E, X, Y, Ar, R¹, R², R³, R⁴, R⁵ and R⁶ are as defined above.

The reaction scheme (3) is a process for producing the compound (I) of the present invention by reacting a compound (IVa) with a compound (Va).


25 This reaction can be carried out under conditions similar to the reaction scheme (1).

The molar ratio of the starting materials may be

optionally set, but the compound (Va) may be used in an amount of from 0.8 to 1.5 mols per mol of the compound (IVa).

Reaction scheme (4)

5



10


wherein A, B, D, E, X, Ar, R^1 , R^2 , R^3 , R^4 , R^5 and R^6 are as defined above, and W is a halogen atom such as a chlorine atom, a bromine atom or an iodine atom, an alkyl(aryl)thio group such as a methylthio group, a benzylthio group or a phenylthio group, or an alkyl(aryl)oxy group such as a methoxy group, a benzyloxy group or a phenyloxy group.

The reaction scheme (4) is a process for producing the compound (I) of the present invention by reacting the compound (IVb) with a compound (Vb) or a compound (Vc). (When the compound (Vc) is employed, R^5 in the compound (I) will be a hydrogen atom.)

This reaction can be accomplished by heating or cooling the compound (IVb) and the compound (Vb) or the compound (IVb) and the compound (Vc), in a solvent or in the absence of a solvent, and may be carried out under conditions similar to the reaction scheme (1).

The molar ratio of the starting materials may optionally be set, but the compound (Vb) or the compound (Vc) may be used in an amount of from 0.8 to 1.5 mols per mol of the compound (IVb).

5 Reaction scheme (5)




wherein A, B, D, E, X, W, Ar, R¹, R², R³, R⁴, R⁵ and R⁶ are as defined above.

15 The reaction scheme (5) is a process for producing the compound (I) of the present invention by reacting a compound (VIa) with a compound (VIIa).

This reaction can be accomplished by heating or cooling the compound (VIa) and the compound (VIIa) in a solvent or in the absence of a solvent, and may be
20 carried out under conditions similar to the reaction scheme (1).

The molar ratio of the starting materials may optionally be set, but the compound (VIa) may be used in an amount of from 0.8 to 1.5 mols per mol of the compound
25 (VIIa).

Reaction scheme (6)




wherein A, B, D, E, X, Y, Ar, R¹, R², R³, R⁴, R⁵ and R⁶ are as defined above.

10 The reaction scheme (6) is a process for producing the compound (I) of the present invention by reacting a compound (VIb) with a compound (VIIb).

This reaction can be carried out under conditions similar to the reaction scheme (1).

15 The molar ratio of the starting materials may optionally be set, but the compound (VIb) may be used in an amount of from 0.8 to 1.5 mols per mol of the compound (VIIb).

Reaction scheme (7)



25

wherein A, B, D, E, X, Y, Ar, R¹, R², R³, R⁴, R⁵ and R⁶ are as defined above.

The reaction scheme (7) is a process for producing the compound (I) of the present invention by reacting a compound (VIII) with a compound (IX).


This reaction can be carried out under conditions
5 similar to the reaction scheme (1).

The molar ratio of the starting materials may optionally be set, but the compound (IX) may be used in an amount of from 0.8 to 1.5 mols per mol of the compound (VIII).

10 Now, processes for producing starting materials for the compounds of the present invention will be described.

Among the starting materials for the compounds of the present invention, the compound (IIa) and the compound (IIb) can be produced by the processes shown by
15 the reaction scheme (8).

Reaction scheme (8)



20

wherein A, E, Y, R¹, R², R³ and R⁶ are as defined above, R⁸ is, for example, a methyl group, a trifluoromethyl group, a phenyl group or a 4-methylphenyl group, and Z is a protective group for an amino group, such as a formyl group, an acetyl group, a benzyloxycarbonyl group or a t-butoxycarbonyl group.

The compound (IIa) can be produced by condensing


the compound (IIaa) with the compound (IX) to obtain the compound (IIab), followed by halogenation (the halogenating reagent may be a chlorinating reagent such as phosphorus pentachloride, thionyl chloride, sulfuryl chloride, chlorine-triphenylphosphine or carbon tetrachloride-triphenylphosphine, a brominating reagent such as phosphorus tribromide, phosphorus pentabromide, thionyl bromide, sulfuryl bromide, bromine-triphenylphosphine or carbon tetrabromide-triphenylphosphine, or an iodinating reagent such as iodine-triphenylphosphine), or reacting it with R^8SO_2Cl , or by halogenating the compound (IIaa) or reacting it with R^8SO_2Cl to obtain a compound (IIac), followed by condensing it with the compound (IX).

15 The compound (IIb) can be produced by reacting the compound (IIa) with the compound (Xb) or reacting the compound (IIa) with the compound (Xa) to obtain the compound (IIbb), followed by removal of the protective group, or by reacting the compound (IIac) with the compound (Xa) to obtain the compound (IIba), followed by reacting it with the compound (IX) to obtain the compound (IIbb), followed by removal of the protective group, or conducting the removal of the protective group first to obtain the compound (IIbc), followed by reacting it with the compound (IX), or by reacting the compound (IIac) with the compound (Xb) to obtain the compound (IIbc), followed by reacting it with the compound (IX) or

protecting it to obtain the compound (IIba), followed by reacting it with the compound (IX) to obtain the compound (IIbb), followed by removal of the protective group.

Among the starting materials for the compounds of the present invention, the compound (IVa) can be produced by the processes shown by the reaction scheme (9).

Reaction scheme (9)




wherein A, B, E, Y, R^1 , R^2 , R^3 , R^6 and R^8 are as defined above.

The compound (IVa) can be produced by reacting the compound (IIa) with the compound (XIb) or reacting the compound (IIb) with the compound (XIa) to obtain the compound (IVab), followed by halogenating it or reacting it with R^8SO_2Cl , or by reacting the compound (IIac) with the compound (XIb) or reacting the compound (IIbc) with the compound (XIa) to obtain the compound (IVaa), followed by reacting it with the compound (IX) to obtain the compound (IVab), followed by halogenating it or reacting it with R^8SO_2Cl .

Among the starting materials for the compounds of the present invention, the compound (IVb) can be produced by the processes shown by the reaction scheme (10).

Reaction scheme (10)




wherein A, B, E, Y, Z, R¹, R², R³, R⁴ and R⁵ are as defined above.

The compound (IVb) can be produced by removing the protective group of the compound (IVbb) or reacting the
5 compound (IIa) with the compound (XIId). The intermediate (IVbb) can be produced by reacting the compound (IIb) with the compound (XIId), reacting the compound (IVa) with the compound (XIIa), reacting the compound (IVba) with the compound (IX), or reacting the
10 compound (IIa) with the compound (XIId).

Among the starting materials for the compounds of the present invention, the compound (VIa) can be produced by the processes shown by the reaction scheme (11).

Reaction scheme (11)



wherein A, B, E, X, Y, W, R^1 , R^2 , R^3 , R^4 and R^6 are as defined above.


20 The compound (VIa) can be produced by reacting the compound (IIb) with the compound (XIIIb), reacting the compound (IVa) with the compound (XIIIa), reacting the compound (VIaa) with the compound (IX), reacting the compound (IIa) with the compound (XIIIc), or reacting the

25 compound (IVb) with the compound (XIIId).

Among the starting materials for the compounds of the present invention, the compound (VIb) can be produced

by the processes shown by the reaction scheme (12).

Reaction scheme (12)




wherein A, B, E, X, Y, W, R^1 , R^2 , R^3 , R^4 , R^5 and R^6 are as defined above.

The compound (VIb) can be produced by reacting the compound (VIa) with the compound (XIVa), reacting the compound (IVa) with the compound (XIVb), reacting the compound (IIa) with the compound (XIVc), reacting the compound (IIb) with the compound (XIVd), reacting the

compound (IVb) with the compound (XIVe), or reacting the compound (IVba) with the compound (IX).

Among the starting materials for the compounds of the present invention, the compound (VIII) can be produced by the processes shown by the reaction scheme (13).

Reaction scheme (13)



wherein A, B, D, X, Y, W, Ar, R¹, R², R³, R⁴, R⁵, R⁶ and R⁷ are as defined above.


The compound (VIII) can be produced by reacting the compound (VIaa) with the compound (VIIa), reacting the
 5 compound (IIac) with the compound (IIIa), reacting the compound (VIba) with the compound (VIIf), reacting the compound (IIbc) with the compound (IIIb), removing the protective group of the compound (IVba) to obtain the compound (IVbc), followed by reacting it with the
 10 compound (Vb), or halogenating the compound (IVaa) or reacting it with R⁸SO₂Cl to obtain the compound (IVac), followed by reacting it with the compound (Va).

The reactions of the following compounds disclosed in the reaction schemes (8) to (13), i.e. (VIaa) and
 15 (VIIa), (IIac) and (IIIa), (IIbc) and (IIIb), (VIba) and (VIIf), (IVbc) and (Vb), (IVac) and (Va), (IVb) and (XIVe), (IIb) and (XIVd), (IIa) and (XIVc), (VIA) and (XIVa), (IVa) and (XIVb), (IVa) and (XIIIa), (IIb) and (XIIIb), (IIa) and (XIIIc), (IVb) and (XIIId), (IIac) and
 20 (XIIb), (IIa) and (XIIb), (IIbc) and (XIIa), (IIb) and (XIIa), (IIb) and (XIIb), (IVa) and (XIIa), (IIa) and (XIIc), (IIa) and (XIId), (IIac) and (Xa), (IIa) and (Xa), (IIac) and (Xb), (IIa) and (Xb), (VIaa) and (IX), (VIba) and (IX), (IVba) and (IX), (IVaa) and (IX), (IIaa)
 25 and (IX), (IIac) and (IX), (IIba) and (IX), and (IIbc) and (IX), can be carried out under conditions similar to the reaction scheme (1). The reactions may be carried

out also in the absence of a solvent. The molar ratios of the compounds may be optionally set, but they may be within a range of from 0.1:1 to 1:0.1.

The intermediates (IVba), (IVbc), (VIaa) and (VIba) disclosed in the reaction schemes (10) to (13) can be produced by the processes shown by the reaction schemes (14) to (16).

Reaction scheme (14)




wherein A, B, Y, Z, R^1 , R^2 , R^4 and R^6 are as defined above.

The compound (IVba) can be produced by reacting the compound (IIbc) with the compound (XIIb), reacting the compound (IVac) with the compound (XIIa), or reacting the

compound (IIac) with the compound (XIIc).

The compound (IVbc) can be produced by reacting the compound (IIac) with the compound (XIId), or by reacting the compound (IIac) with the compound (XIIc) to obtain the compound (IVba), followed by removing the protective group.

Reaction scheme (15)




wherein A, B, X, Y, W, R^1 , R^2 , R^4 and R^6 are as defined above.

The compound (VIaa) can be produced by reacting the

compound (IIbc) with the compound (XIIIb), reacting the compound (IVac) with the compound (XIIIa), reacting the compound (IIac) with the compound (XIIIc), or reacting the compound (IVbc) with the compound (XIIId).

5 Reaction scheme (16)




20 wherein A, B, X, Y, W, R^1 , R^2 , R^4 , R^5 and R^6 are as defined above.

The compound (VIba) can be produced by reacting the compound (VIaa) with the compound (XIVa), reacting the compound (IVac) with the compound (XIVb), reacting the compound (IIac) with the compound (XIVc), reacting the compound (IIbc) with the compound (XIVd), or reacting the compound (IVbc) with the compound (XIVe).

The reactions of the following compounds disclosed in the reaction schemes (14) to (16), i.e. (IIac) and (XIIc), (IIac) and (XIId), (IIbc) and (XIIb), (IVac) and (XIIa), (IVac) and (XIIIa), (IIbc) and (XIIIb), (IIac) and (XIIIc), (IVbc) and (XIIId), (VIaa) and (XIVa); (IVac) and (XIVb), (IIac) and (XIVc), (IIbc) and (XIVd), and (IVbc) and (XIVe), can be carried out under conditions similar to the reaction scheme (1). Further, the reactions may be carried out also in the absence of a solvent. The molar ratios of the compounds can be optionally set, but they may be within a range of from 0.1:1 to 1:0.1.

The processes shown by the reaction scheme (17) may be employed as processes for producing the benzimidazole structure.

Reaction scheme (17)



- wherein E, Y, R¹, R² and R³ are as defined above, E¹ is a single bond or a methylene group which may optionally be substituted by a C₁₋₄ alkyl group, J is AOH, AY, ANR⁶H, ANR⁶Z, ANR⁶BY, ANR⁶BOH, ANR⁶BNR⁴H, ANR⁶BNR⁴Z, ANR⁶BNR⁴C(=X)W, ANR⁶BNR⁴C(=X)NR⁵H or ANR⁶BNR⁴C(=X)NR⁵DAr (wherein A, B, D, X, Y, Z, W, Ar, R⁴, R⁵ and R⁶ are as defined above), and G is COOH, COCl, COBr, CONH₂, CSNH₂, CHO, CN, COOR⁹ (wherein R⁹ is a C₁₋₄ alkyl group, a C₁₋₄ acyl group, a phenyl group or a benzyl group),
- 5 ANR⁶BNR⁴C(=X)W, ANR⁶BNR⁴C(=X)NR⁵H or ANR⁶BNR⁴C(=X)NR⁵DAr (wherein A, B, D, X, Y, Z, W, Ar, R⁴, R⁵ and R⁶ are as defined above), and G is COOH, COCl, COBr, CONH₂, CSNH₂, CHO, CN, COOR⁹ (wherein R⁹ is a C₁₋₄ alkyl group, a C₁₋₄ acyl group, a phenyl group or a benzyl group),
- 10 C(=NH)OR¹⁰, CH(OR¹⁰)₂ (wherein R¹⁰ is a C₁₋₄ alkyl group, a phenyl group or a benzyl group) or CONHNHR⁹ (wherein R⁹ is as defined above).

The benzimidazole derivative of the formula (XVc) can be prepared by condensing the diaminobenzene derivative of the formula (XVa) with the compound (XVI).

15 Further, the benzimidazole derivative of the formula (XVd) can be produced by condensing the diaminobenzene derivative of the formula (XVb) with the compound (XVI), or by reacting the compound (XVc) with the compound (IX).

20 The intermediate (XVb) can be produced by reacting the compound (XVa) with the compound (IX), or by condensing the compound (IXa) under a reducing condition.

With respect to the production conditions, reference may be made to the methods disclosed in e.g. J.

25 Org. Chem., 28, 1931 (1963); J. Chem. Soc., 2238 (1953); J. Am. Chem. Soc., 77, 5652 (1955); J. Chem. Soc., 673 (1956); J. Am. Chem. Soc., 73, 5907 (1951); J. Am. Chem.


Soc., 70, 2415 (1948); J. Chem. Soc., 625, (1943); Khim. Geterotsikl. Soedin., 5, 684 (1982); J. Org. Chem., 56(6), 2260 (1991); Synth. Commnn., 16(1), 35 (1986); Khim. Geterotsikl. Soedin., 71 (1980); J. Chem. Soc. C., 5 20 (1967); Chim. Ther., 2, 95 (1967); J. Org. Chem., 27, 2163 (1962); Chem. Pharm. Bull., 12, 773 (1964); J. Chem. Soc., 2296 (1959); J. Am. Chem. Soc., 79, 4391 (1957); J. Chem. Soc., 1401 (1949).

By the above processes, the compounds (IIaa),
10 (IIac), (IIbc), (IIba), (IVac), (IVaa), (IVbc), (IVba),
(VIaa), (VIba) and (VIII) may be produced directly from
the compound (XVa). Further, the compounds (IIab),
(IIa), (IIb), (IIbb), (IVa), (IVab), (IVbb), (IVb),
(VIa), (VIb) and (I) may be produced directly from the
15 compound (XVb).

For the production of the compounds (XVa) and
(XVb), the processes shown in the reaction scheme (18)
may be employed.

58

Reaction scheme (18)



wherein E, Y, R¹, R² and R³ are as defined above.

15 The compound (XVa) can be produced by reacting the compound (XVIIa) with ammonia to obtain the compound (XVIIb), followed by reducing it. Further, the compound (XVb) can be produced by reacting the compound (XVIIa) with the compound (IXb) to obtain the compound (XVIIc),

20 followed by reducing it.

As described in the foregoing, the present inventors have found that the compound of the formula (I) of the present invention is a superior compound as a strong antiallergic agent, and it is not only useful as

25 an active ingredient for a preventive or curing agent for pollinosis, urticaria, atopic dermatitis, allergic rhinitis and asthma etc., but also effective against

other substance P related diseases, for example, eye diseases such as conjunctivitis and spring catarrh; inflammatory diseases such as chronic rheumatoid arthritis; pains such as migraine, headache, toothache
5 and aches accompanying various diseases; gastrointestinal diseases such as ulcerative colitis and Crohn's disease; and mental diseases such as depression and dysthymia. Thus, the present invention provides a pharmaceutical composition containing the compound of the present
10 invention in an amount effective for treatment of these diseases.

The mode of administration of the compound of the present invention may be parenteral administration of an injection (hypodermic, intravenous, intramuscular or
15 intraperitoneal injection), an ointment, a suppository or an aerosol or oral administration of tablets, capsules, granules, pills, a syrup, a liquid, an emulsion or a suspension.

The pharmacological or veterinary composition
20 containing a compound of the present invention contains the compound of the present invention in an amount of from about 0.01 to 99.5%, preferably from about 0.1 to 30%, based on the total weight of the composition.

In addition to the compound of the present
25 invention, other pharmacological or veterinary active compound may be incorporated into the composition. Such a composition may contain a plurality of compounds of the

71416-175

60

present invention.

The effective dose of the compound of the present invention is usually from about 0.003 to 1.5 g, preferably from about 0.01 to 0.6 g, per an adult per
5 day, although its clinical dose depends on the age, weight, sensitivity and condition of the patient. However, if necessary, the dose may be out of the above-mentioned range.

The compounds of the present invention may be formulated
10 into various formulations together with pharmaceutically acceptable carriers or diluents suitable for administration in accordance with pharmaceutically conventional methods.

Namely, tablets, capsules, granules or pills for oral administration, may be prepared by using an
15 excipient such as sugar, lactose, glucose, starch or mannitol; a binder such as hydroxypropylcellulose, syrup, gum arabic, gelatin, sorbitol, tragacanth gum, methylcellulose or polyvinylpyrrolidone; a disintegrant such as starch, carboxymethylcellulose or its calcium
20 salt, microcrystalline cellulose or polyethylene glycol; a gloss agent such as talc, magnesium or calcium stearate or silica; or a lubricant such as sodium laurate or glycerol.

Injectons, solutions, emulsions, suspensions,
25 syrups or aerosols, may be prepared by using a solvent for the active ingredient such as water, ethyl alcohol, isopropyl alcohol, propylene glycol, 1,3-butylene glycol

or polyethylene glycol; a surfactant such as a sorbitan fatty acid ester, a polyoxyethylene sorbitan fatty acid ester, a polyoxyethylene fatty acid ester, a polyoxyethylene ether of hydrogenated castor oil or
5 lecithin; a suspending agent such as a cellulose derivative such as a sodium salt of carboxymethyl or methylcellulose, or a natural rubber such as tragacanth gum or gum arabic; or a preservative such as a
10 paraoxybenzoic acid ester, benzalkonium chloride or a salt of sorbic acid.

Ointments for percutaneous absorption may be prepared by using white soft paraffin, liquid paraffin, a higher alcohol, macrogol ointment, hydrophilic ointment or an aqueous gel-type vehicle.

15 Suppositories may be prepared by using e.g. cacao butter, polyethylene glycol, lanolin, fatty acid triglyceride, coconut butter or polysorbate.

BEST MODE FOR CARRYING OUT THE INVENTION

EXAMPLES

20 Now, the present invention will be described in further detail with reference to Examples (including Preparation Examples, Formulation Examples and Test Examples). However, it should be understood that the present invention is by no means restricted by these
25 specific Examples.

The symbol "m.p." indicates "melting point".

REFERENCE EXAMPLE 1

N-methyl-N-(benzimidazol-2-yl)-N'-methyl-N'-t-butoxycarbonyl-1,3-propylenediamine

A solution comprising 1.1 g of 2-
5 chlorobenzimidazole and 1.6 g of N,N'-dimethyl-1,3-propylenediamine was heated at a temperature of from 120 to 130°C for two hours. After cooling, the solution was diluted with 50 ml of chloroform and washed with 30 ml of a 1N potassium carbonate aqueous solution. It was dried
10 over anhydrous sodium sulfate, and then the solvent was distilled under reduced pressure. The obtained residue was dissolved in 50 ml of chloroform, and 5 g of di-t-butyl dicarbonate was added thereto. The mixture was left to stand at room temperature for one hour, and then
15 the solvent was distilled off under reduced pressure. The obtained residue was crystallized from diethyl ether to obtain 2.1 g of the above identified compound as pale brown crystals.

REFERENCE EXAMPLE 2

20 N-methyl-N-(benzimidazol-2-yl)-N'-methyl-N'-t-butoxycarbonyl-1,2-ethylenediamine

In the same manner as in Reference Example 1, 1.1 g of the above identified compound was obtained as pale brown crystals, from 1.0 g of 2-chlorobenzimidazole and
25 4.0 g of N,N'-dimethyl-1,2-ethylenediamine.

REFERENCE EXAMPLE 3

N-methyl-N-(benzimidazol-2-yl)methyl-N'-methyl-N'-t-

butoxycarbonyl-1,3-propylenediamine

4.0 g of 2-chloromethylbenzimidazole was added under cooling with ice to a solution comprising 5.0 g of N,N'-dimethyl-1,3-propylenediamine and 30 ml of ethanol, and the mixture was stirred for one hour. The mixture was returned to room temperature and stirred overnight, whereupon the solvent was distilled off under reduced pressure. To the obtained residue, 50 ml of water and 50 ml of chloroform were added, and potassium carbonate was added until the mixture became basic. The organic layer was taken and dried over anhydrous potassium sulfate, and then, the solvent was distilled off under reduced pressure. To the obtained residue, 50 ml of chloroform was added, and 8 g of di-t-butyl dicarbonate was added to this solution. The mixture was stirred at room temperature for one hour, and then the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography (eluent: ethyl acetate/ethanol = 9/1) to obtain 7.0 g of the above identified compound as a brown oily substance.

REFERENCE EXAMPLE 4

N-methyl-N-(benzimidazol-2-yl)methyl-N'-methyl-N'-t-butoxycarbonyl-1,2-ethylenediamine

In the same manner as in Reference Example 3, 6.5 g of the above identified compound was obtained as a orange colored oily substance from 8.0 g of N,N'-dimethyl-1,2-ethylenediamine and 5.0 g of 2-chloromethylbenzimidazole.

REFERENCE EXAMPLE 5

N-methyl-N-(1-(4-fluorobenzyl)benzimidazol-2-yl)-N'-methyl-N'-t-butoxycarbonyl-1,3-propylenediamine

A solution comprising 1.0 g of N-methyl-N-(benzimidazol-2-yl)-N'-methyl-N'-t-butoxycarbonyl-1,3-propylenediamine, 540 mg of 4-fluorobenzyl chloride, 3 g of potassium carbonate and 20 ml of dimethylformamide, was reacted at room temperature overnight under a stirring condition. Further, it was reacted at a temperature of from 50 to 60°C for 10 hours. Then, 50 ml of water was added thereto, and the mixture was extracted with ethyl acetate. The extract was dried over anhydrous sodium sulfate (30 ml × 3), and then, the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography (eluent: ethyl acetate) to obtain 1.4 g of the above identified compound as a colorless oily substance.

REFERENCE EXAMPLE 6

N-methyl-N-(1-(4-fluorobenzyl)benzimidazol-2-yl)-N'-methyl-N'-t-butoxycarbonyl-1,2-ethylenediamine

In the same manner as in Reference Example 5, 1.3 g of the above identified compound was obtained as a pale yellow oily substance from 1.0 g of N-methyl-N-(benzimidazol-2-yl)-N'-methyl-N'-t-butoxycarbonyl-1,2-ethylenediamine

REFERENCE EXAMPLE 7

N-methyl-N-(1-(4-fluorobenzyl)benzimidazol-2-yl)methyl-

N'-methyl-N'-t-butoxycarbonyl-1,3-propylenediamine

In the same manner as in Reference Example 5, 5.0 g of the above identified compound was obtained as a pale yellow oily substance from 6.5 g of N-methyl-N-

5 (benzimidazol-2-yl)methyl-N'-methyl-N'-t-butoxycarbonyl-1,3-propylenediamine

REFERENCE EXAMPLE 8

N-methyl-N-(1-(4-fluorobenzyl)benzimidazol-2-yl)methyl-N'-methyl-N'-t-butoxycarbonyl-1,2-ethylenediamine

10 In the same manner as in Reference Example 5, 6.1 g of the above identified compound was obtained as a pale yellow oily substance from 6.0 g of N-methyl-N-(benzimidazol-2-yl)methyl-N'-methyl-N'-t-butoxycarbonyl-1,2-ethylenediamine

15 PREPARATION EXAMPLE 1

N-methyl-N-(1-(4-fluorobenzyl)benzimidazol-2-yl)-N'-methyl-N'-(3,5-bis(trifluoromethyl)benzylaminocarbonyl)-1,3-propylenediamine hydrochloride

2 ml of trifluoroacetic acid was added to 1.3 g of
20 N-methyl-N-(1-(4-fluorobenzyl)benzimidazol-2-yl)-N'-methyl-N'-t-butoxycarbonyl-1,3-propylenediamine, and the mixture was stirred at room temperature for one hour. Then, 50 ml of water and 50 ml of chloroform were added thereto, and potassium carbonate was added thereto until
25 the mixture became basic. The organic layer was taken and dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure, to obtain 970 mg of

a colorless oily substance. To 300 mg of this oily substance, 370 mg of phenyl N-(3,5-bis(trifluoromethyl)benzyl)carbamate was added, and the mixture was heated and stirred at 120°C for two hours.

5 After cooling, the obtained oily substance was purified by silica gel column chromatography (eluent: ethyl acetate/ethanol = 9/1) to obtain 500 mg of a colorless oily substance. 250 mg of this oily substance was dissolved in 3 ml of ethanol, and 1 ml of 28%

10 hydrochloric acid-ethanol was added thereto. The solvent was distilled off under reduced pressure, and the residue was crystallized from diethyl ether to obtain 280 mg of the above identified compound as colorless crystals. (m.p. 170.0-172.0°C)

15 PREPARATION EXAMPLE 2

N-methyl-N-(1-(4-fluorobenzyl)benzimidazol-2-yl)-N'-methyl-N'-(3,5-bis(trifluoromethyl)benzylaminocarbonyl)-1,2-ethylenediamine hydrochloride

In the same manner as in Preparation Example 1, the

20 above identified compound was obtained as colorless crystals from N-methyl-N-(1-(4-fluorobenzyl)benzimidazol-2-yl)-N'-methyl-N'-t-butoxycarbonyl-1,2-ethylenediamine. (m.p. 182.0-185.0°C)

PREPARATION EXAMPLE 3

25 N-methyl-N-(1-(4-fluorobenzyl)benzimidazol-2-yl)methyl-N'-methyl-N'-(3,5-bis(trifluoromethyl)benzylaminocarbonyl)-1,3-

propylenediamine hydrochloride

In the same manner as in Preparation Example 1, the above identified compound was obtained as a pale yellow oily substance from N-methyl-N-(1-(4-fluorobenzyl)benzimidazol-2-yl)methyl-N'-methyl-N'-t-butoxycarbonyl-1,3-propylenediamine.

PREPARATION EXAMPLE 4


N-methyl-N-(1-(4-fluorobenzyl)benzimidazol-2-yl)methyl-N'-methyl-N'-(3,5-bis(trifluoromethyl)benzylaminocarbonyl)-1,2-ethylenediamine hydrochloride

In the same manner as in Preparation Example 1, the above identified compound was obtained as colorless crystals from N-methyl-N-(1-(4-fluorobenzyl)benzimidazol-2-yl)methyl-N'-methyl-N'-t-butoxycarbonyl-1,2-ethylenediamine. (m.p. 144.0-145.0°C)

PREPARATION EXAMPLES 5 to 13

In the same manner as in Preparation Example 1, the compounds shown in Table 2 were prepared in the form of their hydrochlorides.

Table 2



Example No.	R	m.p. (°C)
5		197.0
6		211.0
7		184.0
8		139.0
9		175.0-178.0
10		138.0
11		156.0-159.0
12		176.0
13		178.6

WO 98/50368

PCT/JP98/01986

69

FORMULATION EXAMPLE 1

Tablets

	Compound of the present invention	10 g
	Lactose	260 g
5	Microcrystalline cellulose	600 g
	Corn starch	350 g
	Hydroxypropyl cellulose	100 g
	CMC-Ca	150 g
	<u>Magnesium stearate</u>	<u>30 g</u>
10	Total	1,500 g

The above ingredients were mixed by a conventional method and made into 10,000 sugar coated tablets containing 1 mg of the active ingredient per tablet.

FORMULATION EXAMPLE 2

15 Capsules

	Compound of the present invention	10 g
	Lactose	440 g
	Microcrystalline cellulose	1,000 g
	<u>Magnesium stearate</u>	<u>50 g</u>
20	Total	1,500 g

The above ingredients were mixed by a conventional method and stuffed into gelatin capsules to obtain 10,000 capsules containing 1 mg of the active ingredient per capsule.

WO 98/50368

PCT/JP98/01986

70

FORMULATION EXAMPLE 3

Soft elastic capsules

	Compound of the present invention	10 g
	PEG 400	479 g
5	Saturated fatty acid triglyceride	1,500 g
	Peppermint oil	1 g
	<u>Polysorbate 80</u>	<u>10 g</u>
	Total	2,000 g

The above ingredients were mixed and then stuffed
10 into No. 3 soft gelatin capsules by a conventional method
to obtain 10,000 soft elastic capsules containing 1 mg of
the active ingredient per capsule.

FORMULATION EXAMPLE 4

Ointment

15	Compound of the present invention	1.0 g
	Liquid paraffin	10.0 g
	Cetanol	20.0 g
	White soft paraffin	68.4 g
	Ethyl paraben	0.1 g
20	<u>1-menthol</u>	<u>0.5 g</u>
	Total	100.0 g

The above ingredients were mixed by a conventional
method to obtain 1% ointment.

WO 98/50368

PCT/JP98/01986

71

FORMULATION EXAMPLE 5

Suppository

	Compound of the present invention	1 g
	Witepsol H15*	478 g
5	Witepsol W35*	520 g
	<u>Polysorbate 80</u>	<u>1 g</u>
	Total	1,000 g

*: Tradename for a triglyceride type compound

The above ingredients were melt-mixed by a
10 conventional method and poured into a suppository
container, followed by cooling and solidification to
obtain 1,000 pieces of a 1 g suppository containing 1 mg
of the active ingredient.

FORMULATION EXAMPLE 6

15 Injection

Compound of the present invention	1 mg
Distilled water for injection	5 ml

Whenever required, the injection is prepared by
dissolving the compound in the distilled water.

20 TEST EXAMPLES

Inhibitory effect on substance P and histamine-induced
contraction of the isolated guinea-pig ileum.

Compound

Test compounds were dissolved and diluted in 100%
25 dimethylsulfoxide (DMSO). Substance P (SP, Peninsula
Laboratories or Peptide Institute) and histamine
dihydrochloride (Wako Pure Chemicals) were dissolved and

diluted in distilled water. DMSO in organ bath did not exceed 0.25% v/v.

Methods

Male Hartley guinea-pigs (300-400 g) were killed by
5 a blow to the head. The ileum was removed and the ileal
strips (15-20 mm) were suspended under 0.5 g tension in a
20 ml organ bath containing a modified Tyrode solution
maintained at 30°C and aerated with 95% O₂+5% CO₂.
Responses were recorded isototonically. Tissues were
10 equilibrated for 15 min, and then the constant responses
to histamine (1 μM) were obtained. Then substance P
(0.01 μM) or histamine (0.1 μM) -induced contraction was
obtained after 5 min incubation with or without the test
compounds. Contractile responses to substance P or
15 histamine with the test compound were expressed as a
percentage of those without the test compound. IC₅₀ was
the concentration of the test compound required to
prevent 50% of the contractile response elicited by
substance P or histamine. Compound Nos. of the tested
20 compounds correspond to the numbers of Preparation
Examples.

73

Tested compounds	I C ₅₀ (μ M)	
	Substance P	Histamine
5		
	1	0. 5 9
	2	0. 2 9
	3	1. 1
	4	0. 1 6
10	5	0. 1 0
	6	3. 0
	7	0. 0 2 9
	8	2. 7
	9	0. 0 2 5
15	10	4. 0
	11	0. 1 0
	12	3. 0
	13	0. 2 8
	14	2. 7
	15	0. 0 3 6
	16	2. 8
	17	0. 0 4 1
	18	1. 5
	19	0. 2 0
	20	4. 1
	21	0. 0 4 4
	22	2. 8
	23	0. 0 2 8

INDUSTRIAL APPLICABILITY


The compounds of the present invention exhibit
 25 antagonistic activities against substance P, and they are
 useful as anti-allergic agents.

71416-175

74

CLAIMS:

1. A benzimidazole derivative of the formula (I) or its salt:



wherein:

10 A is a single bond or a C₁₋₂ alkylene group which may optionally be substituted by a C₁₋₄ alkyl group or a C₃₋₄ cycloalkyl group;

R⁶ is a hydrogen atom; or

a C₁₋₄ alkyl group or a C₃₋₄ cycloalkyl group, each of which may optionally be substituted by a phenyl group;

15 B is a C₂₋₃ alkylene group which may optionally be substituted by a C₁₋₄ alkyl group or a C₃₋₄ cycloalkyl group;

X is an oxygen atom, a sulfur atom or NR⁷ (wherein R⁷ is a nitro group, a cyano group or a C₁₋₄ alkoxy group);

20 R¹ and R² which are each independently a hydrogen atom, a halogen atom, a C₁₋₄ alkyl group, a C₃₋₄ cycloalkyl group or a C₁₋₄ alkoxy group;

E is a C₁₋₂ alkylene group which may optionally be substituted by a C₁₋₄ alkyl group or a C₃₋₄ cycloalkyl group;

25 R³ is a phenyl group (which may optionally be substituted by a halogen atom, a C₁₋₄ alkyl group, a C₃₋₄

71416-175

75

cycloalkyl group or a C₁₋₄ alkoxy group), a C₁₋₄ alkoxy group or a benzyloxy group;

R⁴ and R⁵ are each independently a hydrogen atom;
or

5 a C₁₋₄ alkyl group or a C₃₋₄ cycloalkyl group, each of which may optionally be substituted by a phenyl group;

D is a C₁₋₂ alkylene group which may optionally be substituted by a C₁₋₄ alkyl group or a C₃₋₄ cycloalkyl group; and

10 Ar is a phenyl group which may optionally be substituted by a halogen atom, a C₁₋₄ alkyl group, a C₃₋₄ cycloalkyl group, a C₁₋₄ alkoxy group or a trifluoromethyl group.

2. The compound or its salt according to Claim 1,
15 wherein:

A is a single bond, CH₂, CHMe, CH₂CH₂ or CH₂CHMe;

B is CH₂CH₂, CH₂CHMe, CHMeCH₂, CHMeCHMe, CH₂CH₂CH₂, CHMeCH₂CH₂, CH₂CHMeCH₂, CH₂CH₂CHMe, CHMeCHMeCH₂, CHMeCH₂CHMe, CH₂CHMeCHMe or CHMeCHMeCHMe;

20 D is CH₂, CHMe, CH₂CH₂ or CH₂CHMe;

E is CH₂, CHMe, CH₂CH₂ or CH₂CHMe;

Ar is phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-bromophenyl, 3-bromophenyl, 4-bromophenyl,
25 2-iodophenyl, 3-iodophenyl, 4-iodophenyl, 2-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 2-methoxyphenyl, 3-methoxyphenyl,

71416-175

75a

4-methoxyphenyl, 2,3-difluorophenyl, 2,4-difluorophenyl,
2,5-difluorophenyl, 2,6-difluorophenyl, 3,4-difluorophenyl,
3,5-difluorophenyl, 2,3-dichlorophenyl, 2,4-dichlorophenyl,
2,5-dichlorophenyl, 2,6-dichlorophenyl, 3,4-dichlorophenyl,
5 3,5-dichlorophenyl, 2,3-dibromophenyl, 2,4-dibromophenyl,
2,5-dibromophenyl, 2,6-dibromophenyl, 3,4-dibromophenyl,

71416-175

76

3,5-dibromophenyl, 2,3-diiodophenyl, 2,4-diiodophenyl,
 2,5-diiodophenyl, 2,6-diiodophenyl, 3,4-diiodophenyl,
 3,5-diiodophenyl, 2,3-bis(trifluoromethyl)phenyl,
 2,4-bis(trifluoromethyl)phenyl,
 5 2,5-bis(trifluoromethyl)phenyl,
 2,6-bis(trifluoromethyl)phenyl,
 3,4-bis(trifluoromethyl)phenyl,
 3,5-bis(trifluoromethyl)phenyl, 2,3-dimethylphenyl,
 2,4-dimethylphenyl, 2,5-dimethylphenyl, 2,6-dimethylphenyl,
 10 3,4-dimethylphenyl, 3,5-dimethylphenyl, 2,3-dimethoxyphenyl,
 2,4-dimethoxyphenyl, 2,5-dimethoxyphenyl,
 2,6-dimethoxyphenyl, 3,4-dimethoxyphenyl,
 3,5-dimethoxyphenyl, or 2-chloro-5-trifluoromethylphenyl;

X is an oxygen atom, a sulfur atom, N-CN, N-NO₂,
 15 N-OMe, N-OEt or N-OBu,

each of R¹ and R² is hydrogen, fluorine, chlorine,
 bromine, iodine, methyl, ethyl, n-propyl, i-propyl,
 c-propyl, n-butyl, i-butyl, s-butyl, t-butyl, c-butyl,
 methoxy, ethoxy, n-propoxy, i-propoxy, c-propoxy, n-butoxy,
 20 i-butoxy, s-butoxy, t-butoxy or c-butoxy;

R³ is phenyl, 4-fluorophenyl, 4-chlorophenyl,
 methoxy, ethoxy or benzyloxy;

each of R⁴ and R⁵ is hydrogen, methyl, ethyl,
 n-propyl, i-propyl, c-propyl, n-butyl, i-butyl, s-butyl,
 25 t-butyl, c-butyl or benzyl; and

R⁶ is hydrogen, methyl, ethyl, n-propyl, i-propyl,
 c-propyl, n-butyl, i-butyl, s-butyl, t-butyl, c-butyl or
 benzyl.

3. The compound or its salt according to Claim 2,
 30 wherein X is an oxygen atom.

71416-175

77

4. The compound or its salt according to Claim 3, wherein each of R^1 and R^2 is hydrogen.

5. The compound or its salt according to Claim 1, wherein:

5 A is a single bond or CH_2 ;

B is CH_2CH_2 or $CH_2CH_2CH_2$;

D is CH_2 , CHMe or CH_2CH_2 ;

E is CH_2 or CH_2CH_2 ;

10 Ar is phenyl, 2-chlorophenyl, 2-methoxyphenyl, 3,5-dimethylphenyl, 3,5-bis(trifluoromethyl)phenyl, 3,5-dimethoxyphenyl, 2,5-dichlorophenyl or 2-chloro-5-trifluoromethylphenyl;

X is an oxygen atom;

each of R^1 and R^2 is hydrogen;

15 R^3 is 4-fluorophenyl or ethoxy;

each of R^4 and R^5 is hydrogen, methyl or benzyl;

and

R^6 is hydrogen, methyl or benzyl.

6. The compound or its salt according to Claim 5, 20 wherein E is CH_2 , and R^3 is a 4-fluorophenyl group.

7. The compound or its salt according to Claim 6, wherein Ar is 3,5-bis(trifluoromethyl)phenyl.


8. The compound or salt according to claim 1, wherein the compound is N-methyl-N-(1-(4-fluorobenzyl)benzimidazol- 25 2-yl)-N'-methyl-N'-(3,5-

10. The compound or salt according to claim 1, wherein the compound is N-methyl-N-(1-(4-fluorobenzyl)benzimidazol-2-yl)methyl-N'-methyl-N'-(3,5-bis(trifluoromethyl)benzylaminocarbonyl)-1,3-propylenediamine.

11. The compound or salt according to claim 1, wherein
the compound is N-methyl-N-(1-(4-fluorobenzyl)benzimidazol-
15 2-yl)methyl-N'-methyl-N'-(3,5-
bis(trifluoromethyl)benzylaminocarbonyl)-1,2-
ethylenediamine.

12. The compound or salt according to claim 1, wherein the compound is


20



in which R is:

71416-175

79



13. An agent for treating an allergy-related disease,
 10 which is a pharmaceutical or veterinary composition
 containing:


(a) an effective amount of the compound according
 to any one of claims 1 to 12 or a pharmacologically
 acceptable salt thereof, and

15 (b) a pharmaceutically acceptable carrier or
 diluent.

SMART & BIGGAR

OTTAWA, CANADA

PATENT AGENTS



(I)